Search

Amgen Inc

Avatud

SektorTervishoid

414.88 -0.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

409.54

Max

418.55

Põhinäitajad

By Trading Economics

Sissetulek

-3.6B

-1.8B

Müük

1.4B

10B

P/E

Sektori keskmine

25.517

57.002

Aktsiakasum

6.29

Dividenditootlus

2.38

Kasumimarginaal

-18.092

Töötajad

31,500

EBITDA

-416M

3.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-7.87% downside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

2.38%

2.22%

Järgmine tulemuste avaldamine

3. nov 2026

Järgmine dividendimakse kuupäev

11. sept 2026

Järgmine aktsia dividendi kuupäev (ex-date)

21. aug 2026

Turustatistika

By TradingEconomics

Turukapital

21B

225B

Eelmine avamishind

415.57

Eelmine sulgemishind

414.88

Uudiste sentiment

By Acuity

18%

82%

39 / 340 Pingereas Healthcare

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12. aug 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11. aug 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7. aug 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6. aug 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5. aug 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

4. aug 2026, 23:02 UTC

Social Media
News

Amgen reported strong Q2 results but shares are lower in after-market hours amid rising expense forecasts and the discontinuation of obesity candidate AMG 513.

3. aug 2026, 23:01 UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

31. juuli 2026, 20:07 UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

30. juuli 2026, 21:32 UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

29. juuli 2026, 23:26 UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

28. juuli 2026, 20:02 UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

27. juuli 2026, 23:22 UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

24. juuli 2026, 23:31 UTC

Amgen Inc shares are higher in after-market trading, nearing the upper end of their one-month range. No specific news was identified to explain the movement.

23. juuli 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

22. juuli 2026, 23:11 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and positioning above its 20-day moving average.

21. juuli 2026, 23:46 UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20. juuli 2026, 19:56 UTC

Social Media

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17. juuli 2026, 20:02 UTC

Macro Event

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16. juuli 2026, 18:02 UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15. juuli 2026, 19:16 UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14. juuli 2026, 19:16 UTC

News
Macro Event

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13. juuli 2026, 19:46 UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

10. juuli 2026, 23:16 UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9. juuli 2026, 23:01 UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8. juuli 2026, 23:21 UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7. juuli 2026, 19:06 UTC

News

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6. juuli 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2. juuli 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1. juuli 2026, 19:11 UTC

Social Media

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

-7.87% langus

12 kuu keskmine prognoos

Keskmine 384.95 USD  -7.87%

Kõrge 452 USD

Madal 230 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

9

Osta

11

Hoia

2

Müü

Sentiment

By Acuity

39 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat